The identification of the molecular basis of numerous hereditary neurological disorders allowed the feasibility of predictive genetic tests for at-risk family members. In agreement with international guidelines, we tested a protocol for a predictive test to optimize cooperation among specialists, well-being of participants, and organization of clinical activities. The psychiatrist/psychologist did not meet the at-risk subjects, but cooperated with the team, integrating psychological support for participants and clinicians. We enrolled 60 subjects at risk for Huntington disease, and 32 at risk for spinocerebellar ataxias. Seventy-two subjects (78%) continued the visit program; 55 (60%) received the genetic result, and 38 subjects (41%) completed the program. Participation and outcome were similar in both groups. Mean psychological scores were all below significant levels; however, the need for psychological support was recognized for 5 mutation carriers and a non-carrier. Our data provide a methodological example of a simple and safe procedure for a predictive test, and indicate that the clinical conference represents a good setting to handle psychosocial impact associated with disclosure of genetic results in hereditary late-onset disorders.

Keywords:
Neuropsychology counseling, Predictive genetic testing, Triplet repeat disorders, Huntington disease, Spinocerebellar ataxias, Neuropsychological tests
1.
Harper PS, Solden J, Tyler A: Predictive tests in Huntington’s disease; in Harper PS (ed): Huntington’s Disease. London, Saunders, 1996, pp 395–424.
2.
Matilla T, Volpini V, Genís D, Rosell J, Corral J, Dávalos A, Molins A, Estivill X: Presymptomatic analysis of spinocerebellar ataxia type 1 (SCA1) via the expansion of the SCA1 CAG-repeat in a large pedigree displaying anticipation and parental male bias. Hum Mol Genet 1993;2:2123–2128.
3.
International Huntington Association and the World Federation of Neurology Research Group on Huntington’s Chorea: Guidelines for the molecular genetics predictive test in Huntington’s disease. J Med Genet 1994;31:555–559.
4.
US Preventive Services Taskforce: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355–361.
5.
Raymond VM, Everett JN: Genetic counselling and genetic testing in hereditary gastrointestinal cancer syndromes. Best Pract Res Clin Gastroenterol 2009;23:275–283.
6.
Kane RA, Kane RL: Effect of genetic testing for risk of Alzheimer’s disease. N Engl J Med 2009;361:298–299.
7.
Riedijk SR, Niermeijer MF, Dooijes D, Tibben A: A decade of genetic counseling in frontotemporal dementia affected families: few counseling requests and much familial opposition to testing. J Genet Couns 2009;18:350–356.
8.
Cannella M, Simonelli M, D’Alessio C, Pierelli F, Ruggieri S, Squitieri F: Presymptomatic tests in Huntington’s disease and dominant ataxias. Neurol Sci 2001;22:55–56.
9.
Goizet C, Lesca G, Dürr A, French Group for Presymptomatic Testing in Neurogenetic Disorders: Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology 2002;59:1330–1336.
10.
Paneque M, Lemos C, Escalona K, Prieto L, Reynaldo R, Velázquez M, Quevedo J, Santos N, Almaguer LE, Velázquez L, Sousa A, Fleming M, Sequeiros J: Psychological follow-up of presymptomatic genetic testing for spinocerebellar ataxia type 2 (SCA2) in Cuba. J Genet Couns 2007;16:469–479.
11.
The Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:972–983.
12.
Walker FO: Huntington’s disease. Lancet 2007;369:218–228.
13.
Soong BW, Paulson HL: Spinocerebellar ataxias: an update. Curr Opin Neurol 2007;20:438–446.
14.
Storey E, Bahlo M, Fahey M, Sisson O, Lueck CJ, Gardner RJ: A new dominantly inherited pure cerebellar ataxia, SCA30. J Neurol Neurosurg Psychiatry 2009;80:408–411.
15.
Broadstock M, Michie S, Marteau T: Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000;8:731–738.
16.
Richartz-Salzburger E, Mau-Holzmann U, Schott KJ, Buchkremer G: Predictive diagnostics in chorea Huntington: psychotherapeutic implications for counselling. Psychiatr Prax 2006;33:211–217.
17.
Fox S, Bloch M, Fahy M, Hayden MR: Predictive testing for Huntington disease: description of a pilot project in British Columbia. Am J Med Genet 1989;32:211–216.
18.
European Community Huntington’s Disease Collaborative Study Group: Ethical and social issues in presymptomatic testing for Huntington’s disease: a European Community collaborative study. J Med Genet 1993;30:1028–1035.
19.
Tibben A, Duivenvoorden HJ, Vegter-van der Vlis M, Niermeijer MF, Frets PG, van de Kamp JJ, Roos RA, Rooijmans HG, Verhage F: Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. Am J Med Genet 1993;48:137–144.
20.
Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K, Dom R, Fryns JP, Van den Berghe H: Prediction of psychological functioning one year after the predictive test for Huntington’s disease and impact of the test result on reproductive decision making. J Med Genet 1996;33:737–743.
21.
Lawson K, Wiggins S, Green T, Adam S, Bloch M, Hayden MR: Adverse psychological events occurring in the first year after predictive testing for Huntington’s disease. The Canadian Collaborative Study Predictive Testing. J Med Genet 1996;33:856–862.
22.
Mandich P, Jacopini G, Di Maria E, Sabbadini G, Abbruzzese G, Chimirri F, Bellone E, Novelletto A, Ajmar F, Frontali M: Predictive testing for Huntington’s disease: ten years’ experience in two Italian centres. Ital J Neurol Sci 1998;19:68–74.
23.
Brusco A, Gellera C, Cagnoli C, Saluto A, Castucci A, Michielotto C, Fetoni V, Mariotti C, Migone N, Di Donato S, Taroni F: Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol 2004;61:727–733.
24.
The Huntington Study Group: The Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136–142.
25.
Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schöls L, Szymanski S, van de Warrenburg BP, Dürr A, Klockgether T, Fancellu R: Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717–1720.
26.
Derogatis LR: SCL-90-R: Administration, Scoring and Procedures Manual for the R(evised) Version. Baltimore, John Hopkins University School of Medicine, 1977.
27.
Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.
28.
Thombs BD, Taillefer SS, Hudson M, Baron M: Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007;57:1089–1097.
29.
Busseri MA, Tyler JD: Interchangeability of the Working Alliance Inventory and Working Alliance Inventory, Short Form. Psychol Assess 2003;15:193–197.
30.
Hines KA, McCarthy Veach P, Leroy BS: Genetic counselors’ perceived responsibilities regarding reproductive issues for patients at risk for Huntington disease. J Genet Couns 2009, Epub ahead of print.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.